Research article · 15 Apr 2026
Conference abstractPublished 12 Mar 2018
Half dose of Taurolock: Does it work?
Kermanshah University of Medical Sciences, Iran
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background & Aim: Bacteremia is one of the most important complications in central vein catheter used in hemodialysis. TauroLock is known as an effective catheter lock solution (antimicrobial plus anticoagulant solution) in preventing catheter related bacteremia (CRB), but itâÂ?Â?s cost is high and not coverd by the most insurance companies. Therefore, the aim of this study is to investigate the effect of the medication on a half dose for itâÂ?Â?s economic advantages. Materials & Methods: In this clinical trial study, 152 patients were divided into case (n=62) and control groups (n=90). In the case group, for one year, TauroLock and heparin were injected into the catheterâÂ?Â?s lumen (equal dose) but in the control group, only heparin was injected. For detecting bacteremia, blood cultures were obtained. Results: According to the results, there was a significant difference in CRB between the two groups, at the base time, 3, 6 and 12 months after injection of TauroLock (p<0.05). There was a significant difference in CRB, at the base time of 3, 6 and 12 months, after injection of TauroLock for the case group (p<0.05), but there was no significant difference for the control group (p<0.05). A positive effect in decreasing CRB was seen in the patients, based on age, sex, BMI, duration of hemodialysis, level of serum albumin, diabetes mellitus history and serum ferritin. Conclusion: The catheter lock solution TauroLock, even in half dose, after each hemodialysis session, could significantly decrease the rate of CRB in hemodialysis patients.
Subjects
Nephrology & UrologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Nephrology & Therapeutics.
Brief report · 30 Mar 2026
Renal Fibrosis: Targeting Pathways For New Therapies
Brief report · 30 Mar 2026
SGLT2 Inhibitors: A New Era for Diabetic Kidney Disease
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Nephrology & Therapeutics
- SubjectNephrology & Urology
- BylineArticles whose byline prints “Sima Golmohammadi”

